Experimental dengue vaccine provides immunity for over four years : Healthcare Asia Daily News






June 16, 2022


A dengue vaccine candidate developed by Takeda Pharmaceutical (Takeda), TAK-003, has shown promising results in a Phase 3 trial, providing continued protection against dengue fever through 4.5 years (54 months)…

Source: www.healthcareasia.orgRead more